Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
None (5) ·
Akineton (1) ·
Apokyn (1) ·
Artane (1) ·
Azilect (1) ·
Clozaril (1) ·
Cogentin (1) ·
Comtan (1) ·
Dostinex (1) ·
Eldepryl (1) ·
Fanapt (1) ·
Geodon (1) ·
Inapsine (1) ·
Invega (1) ·
ketalar (1) ·
Latuda (1) ·
Laudanum, Dropizol (1) ·
Lithobid (1) ·
Loxitane (1) ·
Mellaril (1) ·
Moban (1) ·
Navane (1) ·
Neupro (1) ·
Nuedexta (1) ·
Ongentys (1) ·
Orap (1) ·
Parlodel (1) ·
Prolixin (1) ·
Saphris (1) ·
Sinemet (1) ·
Stelazine (1) ·
Symmetrel (1) ·
Tasmar (1) ·
Thorazine (1) ·
Trilafon (1) ·
Ultracet, Tramacet (1) ·
Xadago (1)
classes: (Click arrow to add another value)
mechanism:
None (1) ·
5HT1a (1) ·
Butyrophenone D2 antagonist (1) ·
Central and peripheral COMT inhibitor (1) ·
D1/D2/D3 receptor agonist (1) ·
D2 agonist; D1 partial agonist (1) ·
D2 receptor agonist (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
Dopamine precursor (1) ·
Dopamine precursor + DOPA decarboxylase inhibitor (1) ·
Irreversible selective MAO-B inhibitor (2) ·
MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Multi-receptor antagonist; low D2 affinity (1) ·
Muscarinic receptor antagonist (1) ·
Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) ·
NMDA antagonist; dopamine releasing agent (1) ·
NMDA-receptor antagonism (1) ·
Non-selective dopamine receptor agonist (1) ·
Once-daily COMT inhibitor (1) ·
Peripheral COMT inhibitor (1) ·
Phenothiazine D2 antagonist (4) ·
Selective M1 muscarinic antagonist (1) ·
Source of DMT-class tryptamines (1) ·
Source of [[DMT]], bufotenine, and 5-MeO-DMT (1) ·
Source of [[DMT|N,N-dimethyltryptamine]] (1) ·
TBD (1) ·
Thioxanthene D2 antagonist (1) ·
'"`UNIQ--vote-00001580-QINU`"' First FDA-approved treatment for PBA. The 10 mg quinidine daily dose is far below antiarrhythmic levels but sufficient to nearly fully inhibit CYP2D6, the basis of the combination's pharmacokinetic rationale'"`UNIQ--ref-00001581-QINU`"'. (1) ·
µ-opioid agonism (1)
uses:
starting dose:
preparations:
fda max:
duration:
halflife:
None (39) ·
Dextromethorphan substantially prolonged by quinidine's CYP2D6 inhibition (typical extensive metabolizers see ~10× higher AUC); quinidine ~6-8 hours'"`UNIQ--ref-00001583-QINU`"' (1) ·
Tramadol ~5-7 hours (M1 metabolite ~9 hours); acetaminophen 1-3 hours'"`UNIQ--ref-00001530-QINU`"' (1)
bioavailability:
pregnancy:
None (39) ·
Avoid; neonatal opioid withdrawal documented.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; quinidine has been used in pregnancy as antiarrhythmic.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (39) ·
[[USLegal:Prescription only|Rx-only]] in US. Caution with QT-prolonging medicines (quinidine itself is class IA antiarrhythmic, and the dose here, though sub-antiarrhythmic, still contributes to QT)'"`UNIQ--ref-00001585-QINU`"' (1) ·
[[USLegal:Schedule IV|Schedule IV controlled substance]] in US (tramadol was reclassified from non-controlled to Schedule IV in 2014 after recognition of dependence risk) (1)
Showing below up to 41 results in range #1 to #41.